Clinical Trial

Analysis of the Microenvironment of Lung Cancer and Exploration of the Mechanism of Resistance to Immunotherapy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 20, 2022 (before its estimated December 31, 2023 completion). Its status may not reflect the trial's current state.
Summary
The investigators plan to conduct a multiomics analysis（such as, Genomics, proteomics, single cell RNA sequencing, space transcriptomics）of tumor tissue and blood, aiming at analyzing tumor heterogeneity, mapping the microenvironment map of lung cancer and exploring the mechanism of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2022-11-24.
Trial Details
NCT Number NCT05636605
Lead Sponsor The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Collaborators: Second Affiliated Hospital, Zhejiang University, School of Medicine
Conditions Lung Cancer
Enrollment 200 participants
Start Date 2018-01-01
Primary Completion 2023-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2022-12-20